A Study to Assess the Effectiveness and Safety of Vismodegib (Erivedge®) in Participants With Advanced Basal Cell Carcinoma (BCC)

Study Overview
=================
Brief Summary
-----------------
This prospective, observational, cohort study is designed to assess the effectiveness and safety outcomes of vismodegib and to assess actual day-to-day disease and participant management by the physician.

Official Title
-----------------
A Prospective Observational Study of Erivedge® Treatment, Effectiveness, and Safety Outcomes in Patients With Advanced Basal Cell Carcinoma

Conditions
-----------------
Basal Cell Carcinoma

Intervention / Treatment
-----------------
* Drug: Vismodegib


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: BCC that meets one of the study's pre-specified cohort definitions Physician's decision to treat participant with vismodegib as per local label Participant who has not participated in a clinical trial within 90 days prior to study enrollment, with the exception of participants who meet the criteria for Cohort 2 (No Gorlin Syndrome Participants With Prior HPI Exposure) Exclusion Criteria: Female participants are excluded if they are pregnant or if they plan to become pregnant during treatment or within 2 years after end of treatment Male participants with female partners of childbearing potential are excluded if they plan to impregnate their partner during treatment or within 2 months after end of treatment

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| No Gorlin Syndrome Participants With No Prior HPI Exposure<br>BCC participants with advanced disease and no Gorlin syndrome, and who have not been exposed previously to an Hedgehog Pathway Inhibitor (HPI) (e.g., Vismodegib, LDE225) prior to diagnosis of advanced disease; will receive vismodegib therapy in compliance with the physician's standard practice as per local label and will be followed-up for approximately 3 years or until death, withdrawal of consent, sponsor's decision, lost to follow-up or end of study. | Drug: Vismodegib<br>* Vismodegib therapy will be given in compliance with the physician's standard practice as per local label.<br>* Other names: Erivedge®;|
| No Gorlin Syndrome Participants With Prior HPI Exposure<br>BCC participants with advanced disease and no Gorlin syndrome, and who have been exposed previously to an HPI (e.g., during clinical studies with vismodegib [SHH4476g {NCT00833417}, MO25616 {NCT01367665}] or LDE225); will receive vismodegib therapy in compliance with the physician's standard practice as per local label and will be followed-up for approximately 3 years or until death, withdrawal of consent, sponsor's decision, lost to follow-up or end of study. | Drug: Vismodegib<br>* Vismodegib therapy will be given in compliance with the physician's standard practice as per local label.<br>* Other names: Erivedge®;|
| Gorlin Syndrome Participants With/Without Prior HPI Exposure<br>BCC participants with advanced disease and Gorlin syndrome, and who have or have not been previously exposed to an HPI (e.g., during clinical studies); will receive vismodegib therapy in compliance with the physician's standard practice as per local label and will be followed-up for approximately 3 years or until death, withdrawal of consent, sponsor's decision, lost to follow-up or end of study. | Drug: Vismodegib<br>* Vismodegib therapy will be given in compliance with the physician's standard practice as per local label.<br>* Other names: Erivedge®;|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Percentage of Participants With Clinical Response as Assessed by Investigator According to Response Evaluation Criteria in Solid Tumors (RECIST) Version 1.1 (v1.1) |  | From the date of first treatment up to the date of progression or death from any cause (up to approximately 3 years) | 
| Time to Clinical Response as Assessed by Investigator According to RECIST v1.1 |  | From the date of first treatment until the date of first documented confirmed complete response (CR) or partial response (PR) (whichever occurs first) (up to approximately 3 years) | 
| Duration of Clinical Response as Assessed by Investigator According to RECIST v1.1 |  | From the date of occurrence of first clinical response up to the date of progression or death from any cause (up to approximately 3 years) | 
| Percentage of Participants who Experience a Recurrence |  | From Baseline up to end of study (up to approximately 3 years) | 
| Progression-Free Survival (PFS) as Assessed by Investigator According to RECIST v1.1 |  | From the date of first treatment up to the date of progression or death from any cause (up to approximately 3 years) | 
| Overall survival (OS) |  | From the date of first treatment until death due to any cause (up to approximately 3 years) | 
| Percentage of Participants With Adverse Events |  | From Baseline up to end of study (up to approximately 3 years) | 
| Duration of Vismodegib Treatment |  | Baseline up to approximately 3 years | 
| Percentage of Participants With Vismodegib Treatment Interruption |  | Baseline up to approximately 3 years |